Viewpoint: an explanation for the cardiovascular effects of bevacizumab and rofecoxib?
Barnard
Keith
K
D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002317:Cardiovascular Agents / Q000494:pharmacology*; D002319:Cardiovascular System / Q000187:drug effects*; D051546:Cyclooxygenase 2 / Q000502:physiology; D006801:Humans; D007783:Lactones / Q000494:pharmacology*; D013450:Sulfones / Q000494:pharmacology*; D042461:Vascular Endothelial Growth Factor A / Q000502:physiology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D002317:Cardiovascular Agents; D007783:Lactones; D013450:Sulfones; D042461:Vascular Endothelial Growth Factor A; C116926:rofecoxib; D000068258:Bevacizumab; D051546:Cyclooxygenase 2